Lucid Diagnostics Inc. Common Stock LUCD · Stock Open Lucid Diagnostics Inc. Common Stock in new tab
Lucid Diagnostics Inc. Common Stock Analysis (LUCD)
Is Lucid Diagnostics Inc. Common Stock a good investment? Lucid Diagnostics Inc. Common Stock (LUCD) is currently trading at 0.7345 USD. Market analysts have a consensus price target of 3.83 USD. This suggests a potential upside from current levels.
Earnings Schedule: Lucid Diagnostics Inc. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.73.
Investor FAQ
Does Lucid Diagnostics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Lucid Diagnostics Inc. Common Stock?
Lucid Diagnostics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.26.
Company Profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Community Discussion